Amenamevir: Studies of Potential CYP2C8‐ and CYP2B6‐Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers

Amenamevir (formerly ASP2151) induces cytochrome P450 (CYP)2B6 and CYP3A4 and inhibits CYP2C8.  We conducted 2 studies, 1 using montelukast as a probe to assess CYP2C8 and the other bupropion to assess CYP2B6.  The montelukast study examined the effect of amenamevir on the pharmacokinetics of montel...

Descripción completa

Detalles Bibliográficos
Autores principales: Dennison, Jeremy, Puri, Adeep, Warrington, Steven, Endo, Takamasa, Adeloye, Temitope, Johnston, Atholl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221039/
https://www.ncbi.nlm.nih.gov/pubmed/29870591
http://dx.doi.org/10.1002/cpdd.578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221039/
https://www.ncbi.nlm.nih.gov/pubmed/29870591
http://dx.doi.org/10.1002/cpdd.578

Ejemplares similares